Cargando…
Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
Prostate cancer remains the most common non-cutaneous malignancy among men in the United States. To discover potential serum-based biomarkers for high-risk prostate cancer, we performed a high-multiplex immunoassay utilizing patient-matched pre-operative and post-operative serum samples from ten men...
Autores principales: | Liu, Shiqin, Garcia-Marques, Fernando, Zhang, Chiyuan Amy, Lee, Jordan John, Nolley, Rosalie, Shen, Michelle, Hsu, En-Chi, Aslan, Merve, Koul, Kashyap, Pitteri, Sharon J., Brooks, James D., Stoyanova, Tanya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027881/ https://www.ncbi.nlm.nih.gov/pubmed/33828176 http://dx.doi.org/10.1038/s41598-021-87155-5 |
Ejemplares similares
-
Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer
por: Liu, Shiqin, et al.
Publicado: (2020) -
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
por: Hsu, En-Chi, et al.
Publicado: (2021) -
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
por: Hsu, En-Chi, et al.
Publicado: (2020) -
Oncogene-mediated metabolic gene signature predicts breast cancer outcome
por: Aslan, Merve, et al.
Publicado: (2021) -
Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay
por: Aslan, Merve, et al.
Publicado: (2021)